RETA is a synthetic peptide that acts as a triple agonist, targeting the Glucagon-like peptide-1 (GLP-1), Glucose-dependent Retatrutide insulinotropic polypeptide (GIP), and Glucagon (GCG) receptors. In laboratory research, it is utilized to study the potentiation of metabolic signaling and the regulation of nutrient-stimulated hormone secretion. Studies focus on its efficacy in modulating glucose homeostasis and observing the synergistic effects of triple-receptor activation on lipid metabolism in experimental models.